y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Company profile
Ticker
YMAB
Exchange
Website
CEO
Claus Juan Møller-San Pedro
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Y-mAbs Therapeutics A/S ...
IRS number
474619612
YMAB stock data
Latest filings (excl ownership)
8-K
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
14 Mar 24
8-K
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
4 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
29 Feb 24
8-K
Results of Operations and Financial Condition
9 Jan 24
8-K
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
18 Oct 23
8-K
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
18 Oct 23
Transcripts
YMAB
Earnings call transcript
2023 Q4
1 Mar 24
YMAB
Earnings call transcript
2023 Q3
14 Nov 23
YMAB
Earnings call transcript
2023 Q2
11 Aug 23
YMAB
Earnings call transcript
2023 Q1
9 May 23
YMAB
Earnings call transcript
2022 Q4
31 Mar 23
YMAB
Earnings call transcript
2022 Q3
12 Nov 22
YMAB
Earnings call transcript
2022 Q2
13 Aug 22
YMAB
Earnings call transcript
2022 Q1
14 May 22
YMAB
Earnings call transcript
2021 Q4
25 Feb 22
YMAB
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
4
MARY TAGLIAFERRI
14 Mar 24
3
MARY TAGLIAFERRI
8 Mar 24
4
Vignesh Rajah
7 Mar 24
4
Thomas Gad
7 Mar 24
4
Susan Laura Smith
7 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Michael J Rossi
14 Feb 24
SC 13G/A
WG Biotech ApS
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 86.57 mm | 86.57 mm | 86.57 mm | 86.57 mm | 86.57 mm | 86.57 mm |
Cash burn (monthly) | 446.00 k | 2.33 mm | 2.58 mm | 1.78 mm | 446.00 k | 2.32 mm |
Cash used (since last report) | 2.67 mm | 13.94 mm | 15.45 mm | 10.63 mm | 2.67 mm | 13.89 mm |
Cash remaining | 83.90 mm | 72.63 mm | 71.12 mm | 75.94 mm | 83.90 mm | 72.68 mm |
Runway (months of cash) | 188.1 | 31.2 | 27.5 | 42.8 | 188.1 | 31.3 |
Institutional ownership, Q3 2023
71.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 102 |
Opened positions | 8 |
Closed positions | 7 |
Increased positions | 31 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 101.93 bn |
Total shares | 31.19 mm |
Total puts | 0.00 |
Total calls | 2.90 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotech ApS WG | 4.18 mm | $130.58 mm |
HBM Healthcare Investments | 3.81 mm | $0.00 |
BLK Blackrock | 2.47 mm | $13.48 bn |
Vanguard | 2.23 mm | $12.16 bn |
Sofinnova Investments | 2.19 mm | $11.96 bn |
Sofinnova Venture Partners X | 2.19 mm | $52.07 mm |
Polar Capital | 2.10 mm | $11.46 bn |
Acorn Bioventures | 1.35 mm | $4.55 mm |
D. E. Shaw & Co. | 1.35 mm | $7.35 bn |
Acadian Asset Management | 811.26 k | $4.42 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Mary Tagliaferri | Common Stock | Grant | Acquire A | No | No | 0 | 4,660 | 0.00 | 4,660 |
12 Mar 24 | Mary Tagliaferri | Stock Option Common Stock | Grant | Acquire A | No | No | 16.09 | 27,900 | 448.91 k | 27,900 |
5 Mar 24 | Susan Laura Smith | Common Stock | Sell | Dispose S | No | No | 16.55 | 1,682 | 27.84 k | 33,918 |
5 Mar 24 | Vignesh Rajah | Common Stock | Sell | Dispose S | No | No | 16.53 | 1,711 | 28.28 k | 33,889 |
5 Mar 24 | Thomas Gad | Common Stock | Sell | Dispose S | No | No | 16.44 | 3,900 | 64.12 k | 158,700 |
News
Y-mAbs Therapeutics Announces Resignation Of Chief Financial Officer, Bo Kruse, Will Remain In The Role Until His Successor Is Identified And Joins The Company
14 Mar 24
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
6 Mar 24
HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Raises Price Target to $22
6 Mar 24
Canaccord Genuity Maintains Buy on Y-mAbs Therapeutics, Raises Price Target to $26
4 Mar 24
BMO Capital Maintains Outperform on Y-mAbs Therapeutics, Raises Price Target to $26
4 Mar 24